HeraMED (ASX:HMD) Debt-to-Revenue : 0.53 (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is HeraMED Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

HeraMED's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.29 Mil. HeraMED's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.00 Mil. HeraMED's annualized Revenue for the quarter that ended in Jun. 2024 was A$0.55 Mil. HeraMED's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.53.

HeraMED Debt-to-Revenue Historical Data

The historical data trend for HeraMED's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeraMED Debt-to-Revenue Chart

HeraMED Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

1.66

4.81

39.16

0.81

0.44

HeraMED Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Revenue	Get a 7-Day Free Trial							0.63	1.13	0.43	0.44	0.53

Competitive Comparison of HeraMED's Debt-to-Revenue

For the Medical Devices subindustry, HeraMED's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HeraMED's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where HeraMED's Debt-to-Revenue falls into.

HeraMED Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

HeraMED's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.266	+	0)	/	0.602
	=	0.44

HeraMED's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.291	+	0)	/	0.546
	=	0.53

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.

HeraMED Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of HeraMED's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

HeraMED Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeraMED Ltd (ASX:HMD) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

201, 697 Burke Road, Suite 4, Camberwell, VIC, AUS, 3124

Website

https://www.hera-med.com

HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.

HeraMED Headlines

No Headlines